Show simple item record

dc.contributor.authorChazan, G
dc.contributor.authorFranchini, F
dc.contributor.authorAlexander, M
dc.contributor.authorBanerjee, S
dc.contributor.authorMileshkin, L
dc.contributor.authorBlinman, P
dc.contributor.authorZielinski, R
dc.contributor.authorKarikios, D
dc.contributor.authorPavlakis, N
dc.contributor.authorPeters, S
dc.contributor.authorLordick, F
dc.contributor.authorBall, D
dc.contributor.authorWright, G
dc.contributor.authorIJzerman, M
dc.contributor.authorSolomon, B
dc.date.accessioned2021-01-18T14:23:52Z
dc.date.issued2020-12
dc.identifier.citationESMO open, 2020, 5 (6)
dc.identifier.issn2059-7029
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4292
dc.identifier.eissn2059-7029
dc.identifier.doi10.1136/esmoopen-2020-001090
dc.description.abstractObjectives: To report clinician-perceived changes to cancer service delivery in response to COVID-19. Design: Multidisciplinary Australasian cancer clinician survey in collaboration with the European Society of Medical Oncology. Setting: Between May and June 2020 clinicians from 70 countries were surveyed; majority from Europe (n=196; 39%) with 1846 COVID-19 cases per million people, Australia (AUS)/New Zealand (NZ) (n=188; 38%) with 267/236 per million and Asia (n=75; 15%) with 121 per million at time of survey distribution. Participants: Medical oncologists (n=372; 74%), radiation oncologists (n=91; 18%) and surgical oncologists (n=38; 8%). Results: Eighty-nine per cent of clinicians reported altering clinical practices; more commonly among those with versus without patients diagnosed with COVID-19 (n=142; 93% vs n=225; 86%, p=0.03) but regardless of community transmission levels (p=0.26). More European clinicians (n=111; 66.1%) had treated patients diagnosed with COVID-19 compared with Asia (n=20; 27.8%) and AUS/NZ (n=8; 4.8%), p<0.001. Many clinicians (n=307; 71.4%) reported concerns that reduced access to standard treatments during the pandemic would negatively impact patient survival. The reported proportion of consultations using telehealth increased by 7.7-fold, with 25.1% (n=108) of clinicians concerned that patient survival would be worse due to this increase. Clinicians reviewed a median of 10 fewer outpatients/week (including non-face to face) compared with prior to the pandemic, translating to 5010 fewer specialist oncology visits per week among the surveyed group. Mental health was negatively impacted for 52.6% (n=190) of clinicians. Conclusion: Clinicians reported widespread changes to oncology services, in regions of both high and low COVID-19 case numbers. Clinician concerns of potential negative impacts on patient outcomes warrant objective assessment, with system and policy implications for healthcare delivery at large.
dc.formatPrint
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0
dc.titleImpact of COVID-19 on cancer service delivery: results from an international survey of oncology clinicians.
dc.typeJournal Article
dcterms.dateAccepted2020-10-24
rioxxterms.versionofrecord10.1136/esmoopen-2020-001090
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc/4.0
rioxxterms.licenseref.startdate2020-12
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfESMO open
pubs.issue6
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume5
pubs.embargo.termsNo embargo
dc.contributor.icrauthorBanerjee, Susana


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc/4.0